TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33118401
Drug: Peppermint extract
Normalized name: peppermint allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peppermint extract (40 drops mixed in 20 cc of tap water every 8 hours)
Study: 33118401
Drug: Distilled water
Normalized name: Distilled Water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Distilled water (40 drops mixed in 20 cc of tap water every 8 hours)
Study: 33653385
Drug: Community-based intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community-based intervention including identification and screening of household contacts, referral of contacts with TB-suggestive symptoms, and household initiation of preventive therapy.
Study: 36209981
Drug: Perioperative chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perioperative chemotherapy with gemcitabine (1000mg/m2) and nab-Paclitaxel (125mg/m2) for 2 preoperative and 4 postoperative cycles (arm A)
Study: 36209981
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy with gemcitabine (1000mg/m2) and nab-Paclitaxel (125mg/m2) for 6 cycles (arm B)
Study: 33813638
Drug: Combined Nd:YAG/Er:YAG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined Nd:YAG/Er:YAG laser therapy (test group)
Study: 33813638
Drug: Turned off
Normalized name: Off! Explore
Approvals — FDA: no, EMA: no, PMDA: no
Description: Turned off laser therapy (control group)
Study: 33176043
Drug: Gabapentin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin (100 mg daily for 4 weeks)
Study: 33176043
Drug: Doxepin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxepin (10 mg daily for 4 weeks)
Study: 36064130
Drug: Autologous platelet-rich
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous platelet-rich gel combined with conventional treatment and TCM
Study: 36064130
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy and TCM
Study: 34155984
Drug: Youper app
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Youper app (AI therapy)
Study: 34210720
Drug: Proactive therapeutic
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proactive therapeutic drug monitoring (TDM) arm with infliximab dosing optimised to target higher trough levels (TLI ≥ 25 μg/mL at week 2, ≥ 20 μg/mL at week 6, and ≥ 10 μg/mL during maintenance therapy)
Study: 34210720
Drug: Standard dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dosing arm with conventional infliximab dosing (5 mg/kg at weeks 0, 2, and 6, and 5 mg/kg 8 weekly thereafter)
Study: 32004214
Drug: Raltitrexed (Ra)
Normalized name: raltitrexed
DrugBank: Raltitrexed (DB00293)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raltitrexed (Ra) with oxaliplatin (L‐OHP)
Study: 33998949
Drug: Vaccine with
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine with 50% effectiveness
Study: 33998949
Drug: Vaccine with
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine with 95% effectiveness
Study: 35985196
Drug: Oligonol® supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oligonol® supplementation (200 mg per day)
Study: 34624157
Drug: Machined surface
Normalized name: hepatitis B surface antigen vaccine Injection [Recombivax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Machined surface (MS) implant sites
Study: 34624157
Drug: Laser-microtextured surface
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser-microtextured surface (LMS) implant sites
Study: 32168217
Drug: Low-dose copper
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose copper (175 mm) intrauterine contraceptive with a flexible nitinol frame
Study: 35796019
Drug: NO2 reduction
Normalized name: REDUCTIC ACID
Approvals — FDA: no, EMA: no, PMDA: no
Description: NO2 reduction treatment (sham particle filtration and real NO2 scrubbing)
Study: 35796019
Drug: Particle filtration
Normalized name: SNAIL SECRETION FILTRATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Particle filtration treatment (HEPA filter and sham NO2 scrubbing)
Study: 35796019
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment (sham particle filtration and sham NO2 scrubbing)
Study: 32500753
Drug: Polatuzumab vedotin
Normalized name: polatuzumab vedotin
DrugBank: Polatuzumab vedotin (DB12240)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Polatuzumab vedotin in combination with bendamustine and rituximab (BR)
Study: 32500753
Drug: Polatuzumab vedotin
Normalized name: polatuzumab vedotin
DrugBank: Polatuzumab vedotin (DB12240)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Polatuzumab vedotin in combination with R-CHOP
Study: 33331637
Drug: Dydrogesterone 40
Normalized name: Dydrogesterone
DrugBank: Dydrogesterone (DB00378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dydrogesterone 40 mg orally, followed by 10 mg orally three times a day until 12 completed weeks of gestation or 1 week after bleeding stopped
Study: 33808079
Drug: Spirulina supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spirulina supplementation (6 g per day)
Study: 36054253
Drug: Doxycycline 100
Normalized name: doxycycline 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline 100 mg daily plus montelukast 10 mg daily
Study: 36054253
Drug: Doxycycline 100
Normalized name: doxycycline 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline 100 mg daily plus placebo
Study: 34126052
Drug: On-site access
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: On-site access to oral PrEP
Study: 34126052
Drug: No on-site
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: No on-site access to oral PrEP (before access)
Study: 34126052
Drug: On-site access
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: On-site access to oral PrEP (within 180 days after access)
Study: 34126052
Drug: No on-site
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: No on-site access to oral PrEP (within 180 days before access)
Study: 33715937
Drug: Crestal level
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crestal level (CL) implants
Study: 33715937
Drug: Supracrestal level
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supracrestal level (SL) implants
Study: 33023487
Drug: rTMS treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: rTMS treatment for upper limb recovery
Study: 36385713
Drug: Topical melatonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical melatonin (25 mg/g) applied twice daily during radiation therapy
Study: 36385713
Drug: Placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream applied twice daily during radiation therapy
Study: 33402034
Drug: Sequential-with-tracing presentation
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential-with-tracing presentation of instructional arrows
Study: 33402034
Drug: Sequential-without-tracing presentation
Normalized name: Trace metal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential-without-tracing presentation of instructional arrows
Study: 33402034
Drug: Sequential presentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential presentation of arrows (both types)
Study: 33718317
Drug: Reactive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reactive treatment intervention targeting household members of clinical malaria cases
Study: 32075590
Drug: Prism Adaptation
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prism Adaptation (PA) treatment
Study: 33951328
Drug: A VitD
Approvals — FDA: no, EMA: no, PMDA: no
Description: A VitD group (800 mg calcium and 0.5 μg active vitamin D)
Study: 33951328
Drug: P-A VitD
Approvals — FDA: no, EMA: no, PMDA: no
Description: P-A VitD group (800 mg calcium, 0.5 μg active vitamin D, and physical exercise)
Study: 33951328
Drug: P-NA VitD
Normalized name: Sodium phosphate P 32
DrugBank: Sodium phosphate P 32 (DB09370)
Approvals — FDA: no, EMA: no, PMDA: no
Description: P-NA VitD group (800 mg calcium, 800 IU non-active vitamin D, and physical exercise)
Study: 32146471
Drug: Rechallenge with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rechallenge with previous treatment lines
Study: 32980725
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of T1C and T2
Study: 35126568
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg of Zintoma (ginger rhizome) capsules
Study: 35126568
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg Zintoma capsules
Study: 35126568
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg placebo capsules (containing chickpea flour)
Study: 35126568
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg placebo capsules
Study: 34621271
Drug: B cell
Normalized name: B cell antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: B cell depleting therapy (anti-CD20 treatment)
Study: 34621271
Drug: B cell
Normalized name: B cell antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: B cell depleting therapy (rituximab vs ofatumumab)
Study: 33788482
Drug: Tropisetron hydrochloride
Normalized name: tropisetron hydrochloride
DrugBank: Tropisetron (DB11699)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tropisetron hydrochloride intravenous (Control)
Study: 35483400
Drug: Imiquimod treatment
Normalized name: Imiquimod
DrugBank: Imiquimod (DB00724)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Imiquimod treatment (self-administered, escalating dosage up to 3 times per week for 4-6 months)
Study: 35813289
Drug: Sevoflurane inhalation
Normalized name: Sevoflurane Inhalation Liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sevoflurane inhalation with manual infusion of remifentanil
Study: 35813289
Drug: Effect-site target-controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Effect-site target-controlled infusion of propofol and remifentanil
Study: 33621601
Drug: Progesterone (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progesterone (100 mg subcutaneously twice daily for up to 5 days)
Study: 32145678
Drug: Clemastine 1
Normalized name: clemastine 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clemastine 1 mg orally twice a day for 90 days
Study: 35921997
Drug: Standard implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard implant
Study: 32527365
Drug: Partner non-treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Partner non-treatment
Study: 32822347
Drug: Artesunate (AS)
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Artesunate (AS) 2 mg/kg oral dose
Study: 32651338
Drug: 7.5 mg
Normalized name: biotin 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg Dalfampridine extended release (D-ER)
Study: 32651338
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg Dalfampridine extended release (D-ER)
Study: 35850588
Drug: Expressive art
Approvals — FDA: no, EMA: no, PMDA: no
Description: Expressive art therapy (EAT) plus usual care (UC)
Study: 32055629
Drug: Inhaled 0.9%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled 0.9% normal saline by ultrasonic nebuliser with warming (UNW)
Study: 32055629
Drug: Oral expectorant
Normalized name: pine tar/wild cherry ORAL EXPECTORANT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral expectorant treatment
Study: 33279662
Drug: RT and
Normalized name: Comfort and Ease KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: RT and BCAA (9 g/day)
Study: 32437857
Drug: Two-step impression
Normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Two-step impression in custom trays with border molding (impression compound) followed by polyether impression
Study: 32993773
Drug: Warfarin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin plus nadroparin
Study: 34765229
Drug: High-volume injection
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-volume injection with corticosteroid
Study: 34765229
Drug: High-volume injection
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-volume injection without corticosteroid
Study: 35605593
Drug: Standard stroke
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard stroke treatment protocol including acupuncture
Study: 35326326
Drug: Chlorogenic acids
Normalized name: chlorogenic acid
DrugBank: Chlorogenic Acid (DB12029)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorogenic acids (CGA) 270 mg
Study: 35640081
Drug: Routine oral
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine oral health education (control group)
Study: 34750670
Drug: Intra wound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra wound vancomycin (1-2 g)
Study: 34538239
Drug: Daily clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily clinical warning signs (CWS) assessment
Study: 34538239
Drug: Daily risk
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily risk scores using 7 CWS and MUAC<10.5cm
Study: 32760749
Drug: Beating the
Normalized name: THE-630
DrugBank: THE-630 (DB16750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beating the Blues US (BtB) - 8-session internet cognitive-behavioral therapy for depression
Study: 33085516
Drug: Purified lycopene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purified lycopene (LYC) supplementation at 20 mg/kg diet for 12 weeks
Study: 33201059
Drug: Topical fluorometholone
Normalized name: Fluorometholone
DrugBank: Fluorometholone (DB00324)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical fluorometholone (FML)
Study: 33201059
Drug: Topical cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical cyclosporine A (CSA) 0.5% eye drops
Study: 33293079
Drug: Concomitant radiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concomitant radiotherapy with chemotherapy (cRT)
Study: 33293079
Drug: Radiotherapy without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radiotherapy without concomitant chemotherapy (RT)
Study: 36177347
Drug: Tenofovir Disoproxil
Normalized name: Tenofovir Disoproxil
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tenofovir Disoproxil (TD) 245 mg
Study: 36177347
Drug: Tenofovir Disoproxil
Normalized name: Tenofovir Disoproxil
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tenofovir Disoproxil Fumarate (TDF) 300 mg
Study: 33200722
Drug: MDT for
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDT for leprosy (600 mg rifampicin, 300 mg clofazimine, 100 mg dapsone monthly; 50 mg clofazimine and 100 mg dapsone daily)
Study: 33200722
Drug: MDT for
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDT for leprosy plus itraconazole (100 mg twice daily)
Study: 33596993
Drug: Metformin (850
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (850 mg p.o. twice/day)
Study: 33596993
Drug: Fermentable fibers
Normalized name: fiber
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fermentable fibers (35 g/day)
Study: 33596993
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of metformin plus fiber
Study: 34674404
Drug: Scheduled anticonvulsants
Normalized name: ANTICONVULSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scheduled anticonvulsants and benzodiazepines as needed
Study: 36102618
Drug: Lung volume
Normalized name: beef lung preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lung volume recruitment (LVR) used twice-daily
Study: 34496899
Drug: Methylphenidate (MPH),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (MPH), administered twice daily, dosage based on age and body weight.
Study: 33446270
Drug: Spinal manipulative
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal manipulative therapy followed by physiotherapeutic scoliosis-specific exercise (PSSE)
Study: 34403137
Drug: No-treatment (no-intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-treatment (no-intervention and supplementation only, n=47)
Study: 33478563
Drug: Robotic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Robotic therapy (1 hour per day for 10 days)
Study: 33478563
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard of care therapy only)
Study: 35042638
Drug: Mobile phone
Normalized name: Chamaemelum nobile extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mobile phone reminders (SMS and follow-up calls) sent three days to and on the due date of the child's schedule for the 1st, 2nd, and 3rd doses of the pentavalent vaccine.
Study: 34487764
Drug: Elective nodal
Normalized name: hetastarch
DrugBank: Hydroxyethyl Starch (DB09106)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elective nodal irradiation (ENI) using ultra-hypofractionated radiation (UHRT) (25 Gy in 5 weekly fractions)
Study: 39702151
Drug: Intravenous dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous dexamethasone 10 mg
Study: 33522839
Drug: Nitrofurantoin treatment
Normalized name: Nitrofurantoin
DrugBank: Nitrofurantoin (DB00698)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitrofurantoin treatment
Study: 33522839
Drug: Fosfomycin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosfomycin treatment
Study: 33658841
Drug: Pregabalin (300-450
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin (300-450 mg/day)
Study: 32842052
Drug: E2/P4 hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2/P4 hormone therapy (TX-001HR)
Study: 34788454
Drug: Zao Ren
Normalized name: Ren shen
DrugBank: Ginseng (DB01404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zao Ren An Shen (ZRAS) capsule
Study: 36377643
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose Zika vaccine (6 antigen units)
Study: 36377643
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose Zika vaccine (3 antigen units)
Study: 32278858
Drug: 80 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg/d of purified anthocyanins
Study: 32278858
Drug: Increasing doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increasing doses of purified anthocyanins
Study: 33442904
Drug: Iron infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron infusion (iron (iii)-hydroxide sucrose)
Study: 32700220
Drug: Peer coach-led
Normalized name: coachwhip stem extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peer coach-led intervention for chronic pain (6 months, contact twice per month)
Study: 33072197
Drug: Cerebrolysin, 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerebrolysin, 50 mL per day for ten days, followed by two treatment cycles with 10 mL per day for ten days
Study: 35120184
Drug: Weekly assessments
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly assessments of Dizziness Handicap Inventory (DHI), MdDS Balance Rating Scale (MBRS), and Hospital Anxiety and Depression Scale (HADS)
Study: 36282051
Drug: Intralesional PPD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional PPD injections
Study: 33020098
Drug: Transcranial magnetic
Normalized name: transcranial magnetic stimulator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcranial magnetic stimulation (TMS) therapy for depression
Study: 33932411
Drug: poly (I:C)
Normalized name: C.I. acid blue 324
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: poly (I:C) treatment
Study: 33159796
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone (60, 40, 30, 20, 15, and 10 mg daily for 1 week each, followed by 5 mg daily for 18 weeks)
Study: 32921501
Drug: Usual dose
Normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual dose pitavastatin (2 mg/d)
Study: 35022459
Drug: Preemptive ultrasound-guided
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preemptive ultrasound-guided transversus abdominis plane (TAP) block with 20 cc of ropivacaine 0.25%
Study: 35022459
Drug: Postoperative ultrasound-guided
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative ultrasound-guided transversus abdominis plane (TAP) block with 20 cc of ropivacaine 0.25%
Study: 33471039
Drug: Liraglutide 3
Normalized name: liraglutide 3.6 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide 3 mg/d
Study: 32413238
Drug: Test product
Normalized name: Patch test product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test product (5-mg olanzapine ODT)
Study: 32413238
Drug: Reference product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference product (5-mg olanzapine ODT)
Study: 37258803
Drug: Dapagliflozin +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin + Sitagliptin + Metformin ER (10 mg + 100 mg + 1000 mg)
Study: 37258803
Drug: Sitagliptin +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin + Metformin SR (100 mg + 1000 mg)
Study: 37258803
Drug: Dapagliflozin +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin + Metformin ER (10 mg + 1000 mg)
Study: 33932394
Drug: 1 mL
Normalized name: ethanol 1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mL of 5 μg.mL‐1 sufentanil (group S) with 30 mL of 0.5% bupivacaine
Study: 33932394
Drug: 1 mL
Normalized name: ethanol 1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mL of 100 μg.mL‐1 dexmedetomidine (group D) with 30 mL of 0.5% bupivacaine